{
  "id": 16587164,
  "title": "BioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate",
  "url": "https://urgent.news/2026/10/26/biontech-dualitybio-breast-cancer-drug-meets-phase-3-trial-goal-but",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T10:08:38.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/biontech-dualitybio-breast-cancer-drug-meets-phase-3-trial-goal-shows-higher-lung-disease"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - On Monday, BioNTech (BNTX) and DualityBiologics, subsidiary of Duality Biotherapeutics (9606.HK) said trastuzumab pamirtecan met the primary endpoint in the Phase 3 DYNASTY-Breast02 trial, showing a statistically significant but modest improvement in progression-free",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Innovent reports cancer drug results in breast, lung, pancreatic tumors",
        "url": "https://urgent.news/2026/10/26/innovent-reports-cancer-drug-results-in-breast-lung-pancreatic-tumors",
        "published": "2026-10-26T03:56:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}